{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:43:35Z","timestamp":1769125415399,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose. SGLT2 inhibitors have been reported to suppress the complications of diabetes and reduce overall mortality. However, little is known about the types of symptoms that may occur in response to an overdose of an SGLT2 inhibitor. Here, we describe a case of intoxication caused by an overdose of an SGLT2 inhibitor.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>An otherwise physically healthy adult woman ingested an overdose of ipragliflozin, an SGLT2 inhibitor, and a polypill of olmesartan medoxomil, and azelnidipine in a suicide attempt. Although her blood ipragliflozin concentration was very high (9516.3\u2009ng\/mL) upon hospital arrival, her initial blood glucose level was normal, and she did not exhibit symptoms such as hypoglycemia or polyuria. Moderate renal dysfunction associated with an estimated glomerular filtration rate of 42.3\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> was observed. Thirty-six hours after ingestion, her blood ipragliflozin concentration decreased to a level equivalent to that observed after a therapeutic dose and her renal function improved almost simultaneously. After improvement in her renal function, the osmotic diuretic effect of the drug progressed. Her blood glucose level declined slightly but was in the normal range due to glucose administration. During the clinical course, fatal hypoglycemia was not observed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our case showed that an overdose of an SGLT2 inhibitor caused toxic effects on renal function, but severe hypoglycemia was not observed. Additional cases of intoxication from SGLT2 inhibitors alone would be helpful to clarify the mechanism of intoxication.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40360-019-0381-z","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T15:02:57Z","timestamp":1578582177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0488-9305","authenticated-orcid":false,"given":"Miho","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Nakade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"381_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/jc.2009-0473","volume":"95","author":"S Nair","year":"2010","unstructured":"Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95:34\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"381_CR2","volume-title":"Ipragliflozin L-proline review report","author":"Evaluation and Licensing Division","year":"2013","unstructured":"Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. Ipragliflozin L-proline review report http:\/\/www.pmda.go.jp\/files\/000206796.pdf; [Accessed Aug 10 2019]. Tokyo: Ministry of Health, Labour and Welfare; 2013."},{"key":"381_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1021\/ml400339b","volume":"5","author":"S Nomura","year":"2014","unstructured":"Nomura S, Yamamoto Y, Matsumura Y, Ohba K, Sakamaki S, Kimata H, et al. Novel Indole-N-glucoside, TA-1887 as a sodium glucose Cotransporter 2 inhibitor for treatment of type 2 diabetes. ACS Med Chem Lett. 2014;5:51\u20135.","journal-title":"ACS Med Chem Lett"},{"key":"381_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"381_CR5","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644\u201357.","journal-title":"N Engl J Med"},{"key":"381_CR6","doi-asserted-by":"publisher","first-page":"i2231","DOI":"10.1136\/bmj.i2231","volume":"353","author":"F Salvo","year":"2016","unstructured":"Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis. BMJ. 2016;353:i2231.","journal-title":"BMJ."},{"key":"381_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"EJ van Bommel","year":"2017","unstructured":"van Bommel EJ, Muskiet MH, Tonneijck L, Kramer MH, Nieuwdorp M, van Raalte DH. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome. Clin J Am Soc Nephrol. 2017;12:700\u201310.","journal-title":"Clin J Am Soc Nephrol"},{"key":"381_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/15563650701779695","volume":"5","author":"SW Smith","year":"2008","unstructured":"Smith SW, Ferguson KL, Hoffman RS, Nelson LS, Greller HA. Prolonged severe hypotension following combined amlodipine and valsartan ingestion. Clin Toxicol (Phila). 2008;5:470\u20134.","journal-title":"Clin Toxicol (Phila)"},{"key":"381_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/0002-9343(86)90276-7","volume":"81","author":"DM Herrington","year":"1986","unstructured":"Herrington DM, Insley BM, Weinmann GG. Nifedipine overdose. Am J Med. 1986;81:344\u20136.","journal-title":"Am J Med"},{"key":"381_CR10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mpmed.2007.08.025","volume":"35","author":"N Buckley","year":"2007","unstructured":"Buckley N, Dawson A, Whyte I. Calcium channel blockers. Medicine. 2007;35:599\u2013602.","journal-title":"Medicine."}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-019-0381-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-019-0381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T01:15:37Z","timestamp":1610068537000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-019-0381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["381"],"URL":"https:\/\/doi.org\/10.1186\/s40360-019-0381-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"10 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In Kanazawa University Hospital, ethics approval is not required for a case report with written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}